At a guess and off the top of my head I would say pipeline, patents, cash in bank, extraordinary (although early) therapeutic results, a potential best in class diagnostic, reliable supply chains, a very large TAM, potential takeover by big pharma (based on recent acquisitions), Alan Taylor himself and finally an eye on the TLX price with a not unrealistic assumption of a better product.
I’ve delved into Cu6 comprehensively, not so much DXB, although I hold it. I think DXB, treating such a rare condition, probably doesn’t have the amount of eyes on it and for the same reason, recruitment is necessarily slower, requiring more extensive timelines etc. Not a criticism, just a fact.
DXB Price at posting:
35.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)